Abstract AB0415 – Table 1. Change from Week 26 in Disease Activity, Functional and Structural Measures Based on Flare Status in Patients Achieving Stable LDA*

Outcome measure Mean (SD)		Visit Mean at Week 26		Mean Change (Δ) from Week 26 to Week 78	
		Flare	No Flare	Flare	No Flare
DAS28(CRP)	ADA Withdrawal	2.2	2.0	1.0 (1.2)	-0.1 (0.6)
	ADA Continuation	2.1	2.0	0.6 (1.1)	-0.2 (0.7)
	MTX Continuation	2.2	2.1	1.0 (1.2)	-0.1 (0.8)
HAQ-DI	ADA Withdrawal	0.4	0.2	0.3 (0.6)	0.0 (0.3)
	ADA Continuation	0.5	0.3	0.2 (0.5)	-0.1 (0.3)
	MTX Continuation	0.4	0.3	0.2 (0.5)	0.0 (0.4)
mTSS	ADA Withdrawal	8.4	11.5	0.3 (0.7)	0.2 (1.1)
	ADA Continuation	6.9	12.7	0.1 (0.5)	-0.1 (0.7)
	MTX Continuation	10.5	9.2	0.1 (0.6)	0.1 (1.0)

*Flare was defined as change in DAS28(CRP) ≥ 0.6 at consecutive visits and DAS28(CRP) ≥ 3.2 .

LDA=low disease activity; DAS28(CRP)=28 joint disease activity score based on C-reactive protein; ADA=adalimumab; MTX=methotrexate; HAQ-DI=health assessment questionnaire disability index; mTSS=modified total Sharp score.

Conclusions: In early RA pts achieving sLDA, flares were generally infrequent; however, they were more prevalent in pts receiving PBO+MTX compared with ADA+MTX. Flares were numerically associated with higher disease activity, functional deterioration, and higher PtGA, underscoring its impact on health-related quality of life and the importance of preventing flares as a therapeutic outcome.

REFERENCE:

- [1] Smolen JS, et al. *Lancet* 2014;383:231–32.

Acknowledgements: AbbVie funded the study (NCT00420927), contributed to its design, and participated in data collection, analysis and interpretation of the data, and in writing, review, and approval of the publication. Medical writing support was provided by Deepa Venkataramani, PhD, of AbbVie

Disclosure of Interest: A. Kavanaugh Grant/research support from: AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB, Consultant for: AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB, Speakers bureau: AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Pfizer, Roche, and UCB, R. van Vollenhoven Grant/research support from: AbbVie, Amgen, Biotest, BMS, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex, Consultant for: AbbVie, Amgen, Biotest, BMS, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex, Speakers bureau: AbbVie, Amgen, Biotest, BMS, Celgene, Crescendo, GlaxoSmithKline, Janssen, Lilly, Merck, Novartis, Pfizer, Roche, UCB, and Vertex, P. Sunkureddi Consultant for: Novartis, Bristol-Myers Squibb, UCB, Pfizer, AbbVie, and Takeda, Speakers bureau: Novartis, Bristol-Myers Squibb, UCB, Pfizer, AbbVie, and Takeda, Y. Zhang Shareholder of: AbbVie, Employee of: AbbVie, J. Suboticki Shareholder of: AbbVie, Employee of: AbbVie, J. Smolen Grant/research support from: from AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Glaxo, Lilly, Pfizer, MSD, Novo Nordisk, Roche, Sandoz, and UCB, Consultant for: AbbVie, Amgen, AstraZeneca, BMS, Celgene, Centocor-Janssen, Glaxo, Lilly, Pfizer, MSD, Novo Nordisk, Roche, Sandoz, and UCB
DOI: 10.1136/annrheumdis-2018-eular.2638

AB0416 ESTIMATING THE SHORT-TERM COSTS ASSOCIATED WITH NON-MEDICAL SWITCHING IN RHEUMATIC DISEASES

A. Gibofsky¹, V. Garg², M. Yang³, C.Z. Qi³, M. Skup². ¹Hospital for Special Surgery-Weill Cornell Medicine, New York; ²AbbVie, Chicago; ³Analysis Group, Inc., Boston, USA

Background: As biosimilars are approved and commercialised for rheumatic diseases, patients may be switched from originator biologic treatment to biosimilars due to perceived cost savings between the two biologic products. However, in the short term, non-medical switching (NMS) may require additional patient education, office visits, lab/imaging tests, and administrative support which could lead to substantial costs.

Objectives: To estimate the short-term costs associated with NMS from originator biologics to biosimilars among stable patients with rheumatic conditions (e.g., rheumatoid arthritis, RA; ankylosing spondylitis, AS; psoriatic arthritis – PsA) from the perspective of a rheumatology medical centre in the United Kingdom.

Methods: An economic model was constructed including two components: the administrative burden for NMS program set-up and support, and the provider burden for initiating and managing NMS. Administrative burden was modelled at the center-level and considered staff time for program set-up, patient education, scheduling, documentation, and departmental meetings from pre-NMS planning

to post NMS implementation (<1 year). The provider burden was modelled at the patient-level and considered the expected additional provider time needed and extra laboratory/imaging tests when managing NMS from the time of switching until 3 month post NMS implementation. Model inputs for the administrative burden came from the literature¹ and for provider burden from survey of physicians. Literature was used to inform both the total number of rheumatology patients that underwent NMS, and the unit cost associated with provider/staff time and laboratory/imaging tests.

Results: From a rheumatology centre perspective, setting up an NMS program and the subsequent administrative support was estimated to cost £19 617 per centre, attributed to general overhead (40%), pharmacist time (26%), consultant time (21%), and nurse time (13%). After the set-up, provider burden for initiating and managing NMS was estimated to be £113 per switched patient. Assuming 5000 patients with relevant rheumatoid conditions in a centre, 572 stable patients with RA, PsA or AS were estimated to switch to biosimilars. The overall short-term cost associated with NMS was estimated to be £84 174 for the entire centre, with 23% attributed to the NMS program set-up and support, and 77% attributed to extra provider time and monitoring (on average £147 cost per switched patient).

Conclusions: Switching stable patients with a rheumatic condition from originator biologics to biosimilars could have considerable short-term costs for a centre. Additional real world studies are needed to better weigh the potential saving vs. cost associated with NMS.

REFERENCE:

- [1] Barnes T, et al. ISPOR 20th Annual European Congress November 4–8 2017. Glasgow, Scotland.

Acknowledgements: Medical writing support was provided by Cinzia Metallo of Analysis Group; this support was funded by AbbVie.

Disclosure of Interest: A. Gibofsky Shareholder of: AbbVie, Amgen, BMS, GSK, Horizon, J and J and Pfizer, Consultant for: AbbVie, Amgen, Celgene, Eli Lilly and Company, Genentech, Horizon, Iroko, Merck, Novartis, Pfizer, Sandoz and UCB, V. Garg Shareholder of: AbbVie, Employee of: AbbVie, M. Yang Employee of: Analysis Group, Inc., which has received consultancy fees from AbbVie, C. Qi Employee of: Analysis Group, Inc., which has received consultancy fees from AbbVie, M. Skup Shareholder of: AbbVie, Employee of: AbbVie
DOI: 10.1136/annrheumdis-2018-eular.7463

AB0417 BIOLOGICAL DRUGS IN THE TREATMENT OF RHEUMATOID ARTHRITIS: REAL LIFE DATA IN A BRAZILIAN MULTICENTRIC STUDY

A. Gómeides¹, G. Pinheiro², A. Santos², C. Albuquerque³, R. Giorgi⁴, S. Radominski⁵, I. Pereira⁶, M. Guimarães⁷, M. Bértolo⁸, P.L. Júnior⁹, K. Bonfiglioli¹⁰, C. Brenol¹¹, M. Cunha¹², L. Mota³. ¹Universidade de Brasília, UnB-Brasília; ²1. Universidade do Estado do Rio de Janeiro, Rio de Janeiro; ³Universidade de Brasília, Brasília; ⁴3. Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo; ⁵4. Universidade Federal do Paraná, Curitiba; ⁶5. Universidade Federal de Santa Catarina, Florianópolis; ⁷6. Universidade Federal de Minas Gerais, Belo Horizonte; ⁸7. Universidade Estadual de Campinas, Campinas; ⁹8. Universidade de São Paulo – Ribeirão Preto, Ribeirão Preto; ¹⁰10. Universidade de São Paulo, São Paulo; ¹¹11. Universidade Federal do Rio Grande do Sul, Porto Alegre; ¹²9. Universidade Federal do Pará, Belém, Brazil

Background: Rheumatoid arthritis (RA) is a chronic disease, characterised by inflammatory involvement of the synovial joints. The "treat to target" concept is well established in the rheumatologic community, however, in many patients, especially in developing countries, its implementation is not feasible. Considering the high costs of treatment com of RA and the limited national epidemiological data available on this disease, we sought to describe the profile of use of biological drugs in Brazilian patients with RA to help the decision-making process by public health managers.

Objectives: To describe the frequency and time of use of biological drugs in Brazilian patients with rheumatoid arthritis.

Methods: The REAL – RA in real life in Brazil – is a multicenter prospective cohort study, with twelve-month follow-up period. To be included in this study, consecutive patients from 11 tertiary rheumatology centres had to meet the 1987 ACR or the 2010 ACR/European League Against Rheumatism (EULAR) criteria. Data were collected during routine clinical care and previous medical records were used as secondary sources. The present study present data taken from the participants' initial assessment. This research was approved by the Ethics Committees of each centre.

Results: A total of 1125 patients were analysed. 89% were women with a mean age of 56.6 years. The main clinic data were: DAS 28 (median)=3.52, HAQ (median)=0.87 and CDAI (median)=9. 1022 (90.84%) used synthetic DMARDs

and 406 (36.09%) biologic therapy. The frequency of use of the biologic therapy was: abatacept (73 patients/6.49%), etanercept (66/5.87%), tocilizumab (60/5.33%), adalimumab (54/4.8%), infliximab (50/4.44%), rituximab (49/4.36%), golimumab (37/3.29%), certolizumab (17, 1.51%). The time of use of the biological drugs is presented in table 1.

Abstract AB0417 – Table 1. Time (in years) of use of biological drugs in patients with rheumatoid arthritis

DRUG	MEAN	MAXIMUM
ABATACEPT	1.95	8
ADALIMUMAB	1.70	12
CERTOLIZUMAB	0.63	2.0
ETANERCEPT	1.49	9.0
GOLIMUMAB	0.65	2.0
INFLIXIMAB	1.56	9.0
RITUXIMAB	1.27	6.0
TOCILIZUMABE	2.0	6.0

Conclusions: The therapeutic profile of this cohort of Brazilian RA patients shows some interesting results. The relatively high number of patients on biologics, compared to other studies, may be related to fact that the centres involved were reference centres, probably dealing with more difficult cases.

REFERENCES:

- [1] Azevedo AB, Ferraz MB, Ciconelli RM. Indirect Costs of Rheumatoid Arthritis in Brazil. *Value in Health* 2008;11(5):869–877.
- [2] Boonen A, Severens JL. The burden of illness of rheumatoid arthritis. *Clin Rheumatol* 2011;30(Suppl 1):S3–S8.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.7090

AB0418

THE EFFECT OF CONCOMITANT METHOTREXATE ON SERUM TNF INHIBITORS LEVELS AND CLINICAL RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS IS DOSE DEPENDENT AND GREATER THAN OTHER DMARDS

A. Martinez-Feito, C. Plasencia, V. Navarro-Compan, B. Hernández-Breijo, M. A. Gonzalez, I. Monjo, L. Nuño, P. Nozal, D. Pascual-Salcedo, A. Balsa. *Immunology Research Group, University Hospital LA PAZ, Madrid, Spain*

Background: Several factors influence on the pharmacokinetics(PK) of TNF inhibitors(TNFi). One of the most relevant influencing factors is the development of antidrug- antibodies(ADA), which is associated with low circulating drug levels and loss of clinical efficacy. Previous studies, mostly about Adalimumab (Ada), have demonstrated a beneficial effect of concomitant use of methotrexate(MTX) in patients(pts) under TNFi therapy by reduction of immunogenicity. There are other csDMARDs(OD) as leflunomide, hydroxycloquine or sulfasalazine which may have also an effect on PK.

Objectives: To investigate the effect of csDMARDs on the presence of serum TNFi levels and on the clinical response during the first year of Ada or Infliximab (Ifx) treatment in RA pts. Secondly, to evaluate if MTX has a dose-dependent effect on these outcomes.

Methods: This is an inception cohort including pts with RA starting Ifx or Ada in a tertiary hospital since 1999. At baseline, 6 and 12 months clinical(DAS28, EULAR response and ΔDAS28) and serological(drug and ADA levels) parameters were measured. Patients were clustered according to the use of concomitant csDMARDs at baseline in three groups: i)TNFi monotherapy;ii)TNFi +MTX;iii) TNFi +OD. Pts within the TNFi +MTX group were also classified according to the MTX dose:MTX <15 mg/week(TNFi +MTX <15) and MTX ≥15 mg/week(TNFi +MTX ≥15).

Results: A total of 92 RA pts[Ada(n=25) or Ifx(n=67)] under TNFi were included. The number and percentage of pts in each group were as follows:TNFi monotherapy,12 pts(13%);TNFi +MTX, 59 pts(64%);TNFi +OD 21 pts(23%). According to MTX dose, the distribution was:TNFi +MTX <15,18 pts(20%);TNFi +MTX ≥15, 41 pts(45%). Considering the overall of pts receiving any dose of MTX, the percentage of them with drug levels after 12 months(71%) was numerically higher than in the other groups(20% in TNFi +OD and 9% in TNFi monotherapy,p=0.1). However, after stratifying pts by MTX dose, we observed that circulating drug levels at 12 months were more frequent in higher dose of MTX(54% of the pts with TNFi +MTX ≥15) compared to patients with TNFi +MTX <15 (17%), with TNFi +OD (20%) and with TNFi monotherapy (9%);p=0.002). According to EULAR

response, pts treated with TNFi +MTX(81%) achieved more frequently a good response compared with the other groups (11% on TNFi +OD and 8% on TNFi monotherapy, p=0.6). Moreover, differences on clinical response were observed depending on MTX dose. While 58% with TNFi +MTX ≥15 were good EULAR responders, 23% with TNFi +MTX <15 achieved this. Overall, the best effect on clinical response was observed in the group of MTX; p=0.4. Finally, the TNFi median survival time(mst) was significantly higher in pts with TNFi +MTX than in pts with TNFi +OD or on TNFi monotherapy(5 years vs 2 years vs 2.15 years, respectively;p=0.03). Analysing by MTX dose, drug survival was superior for high (≥15) and low MTX doses(<15) (mst 5.2 and 3.3, respectively)compared to OD and/or TNFi monotherapy although the difference was not statistically significant p=0.09.

Conclusions: In RA pts under Ifx or Ada treatment, the presence of TNFi in serum, the clinical response and the TNFi survival are influenced by MTX but not by OD. Moreover, a MTX dose-dependent effect is closely associated with these outcomes.

Disclosure of Interest: None declared

DOI: 10.1136/annrheumdis-2018-eular.5389

AB0419

FREQUENCY OF DISEASE FLARE AND STUDY OF THE CD4+CD25+HIGHCD127LOW/- CELL POPULATIONS AFTER DISCONTINUATION OF ANTI-TNFA THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS IN PERSISTENT REMISSION

A. Lo Monaco¹, C.A. Scirè¹, F. Casciano², V. Tisato², P. Secchiero², M. Govoni¹.

¹Department of Medical Sciences-Section of Rheumatology, University of Ferrara and Azienda Ospedaliero-Universitaria Sant'Anna di Cona; ²Department of Morphology, Surgery and Experimental Medicine and LTTA Centre, University of Ferrara, Ferrara, Italy

Background: Rheumatoid arthritis (RA) patients in a prolonged remission status represent a population whose future management has yet to be established. Treg cell function in patients with active RA is assumed to be impaired, a trend that seems to be reversed by TNFalpha antagonist therapy (aTNF). Theoretically a deeper remission may be represented by an immunological resetting of immune system, a condition which could enable to consider the possibility of a drug-free remission.

Objectives: To evaluate the incidence of disease flare after cessation of aTNF in pts in remission together with reconstitution of the CD4 +CD25highCD127low/- Tcell subset respect to those patients in the same remission status with persistent low CD4 +CD25highCD127low/-Tcell population, assuming the Treg populations as a markers of deep remission allowing a better selection of those patients at low-risk of flare after aTNF withdrawal.

Methods: inclusion criteria: patients with RA (>18 years) fulfilling the 1987 ACR classification criteria treated with aTNF and synthetic DMARDs for at least 12 months, in remission (DAS28 <2.6/DAS44 <1.6)>6 months, without glucocorticosteroid. Exclusion criteria:<18 years, glucocorticosteroids within the three months before; another inflammatory disease other than RA; ongoing infections. Intervention: aTNF drug withdrawal with continuation of DMARDs previously associated (MTX or LFN); a 24 months of follow up was performed. Serial clinical and instrumental evaluation, blood sampling and radiographs have been performed according to the scheduled protocol. Treg population and several cytokines/chemokines/growth factors were analysed (Human Cytokine/Chemokine Panel I, Millipore).

Results: 23 patients were included, mean age 53 years (SD 12.3), 68% RF +, 52% ACPA +, DAS28 medium 1.41 (SD 0.48); average duration of illness 9.62 years (SD ±5.73). During the 24 month post-suspension follow-up, for a total of 267 person-months, 11 patients presented a flare, for a flare rate of 3.74/100 person-months (CI95% 1.79–6.88). The average observed exacerbation time from aTNF withdrawal was 14.6 months (SD ±9.32). None statistical predictive value of Treg levels regarding disease outcome after aTNF withdrawal was observed IIR (95% CI) 1.38 (0.82–2.30). None significant correlation among cytokines concentrations and disease status/Treg levels was observed. A correlation was observed between the presence of a synovitis with PD1+* at the baseline and the loss of remission [HR 7.062 (1.64–30.41, p 0.009);*higher values were exclusion criteria]. All 3 patients with positive US (PD1) who had flare-up were asymptomatic at baseline.

Conclusions: 47.8% of pts maintained aTNF-induced remission at 24 months continuing only sDMARDs therapy (MTX). Only in 1 case reintroduction of Adalimumab did not allow to regain clinical remission, which was obtained using another therapeutic target (anti-CTL4). The presence of a residual synovitis, although mild (PD1), was correlated with the risk of exacerbation. Further results will be discussed.